Member Info for inanaco

So you are a Salesman with no science background ......... and you are not Running any Bio Tech or have managed any business .. i get it.

Scancell is not selling or marketing to individuals with no experience ...

I do not think advocacy groups discuss this via twitter

you seem to create an issue when there is not one ........

Rather than discussing the negative ......... look at actually how they can get our products to probably the second biggest market in the world .... and Who might just be interested in a joint venture ?

a far more worthy discussion ...

and you are concerned that you don't get updates ... yet we know of them ? even if they updated the website, the data would still trickle out the same way ...

China is interesting https://prahs.com/blog/2018/07/16/breaking-down-drug-development-barriers-in-china/

capital L .. ouch !

lindy prefers to be called Lindy .. indeed she told me !!! every email is signed Lindy ....

From: Lindy Durrant <Lindy.Durrant@nottingham.ac.uk>

Potentially but we need to show the synergy first in the approved cohort.
Kind Regards,
Lindy

Prof Lindy Durrant
The University of Nottingham
Academic Clinical Oncology
City Hospital Campus
Hucknall Road
Nottingham NG5 1PB

Unless you are Labour Crumbs .. you issue Bonds for shares ... after all its not borrowing .. LOL

Arm Holdings ... back in 2013 ... not bad eh !

Modi1 ... has gone from 70% to 100% mouse survival this caused a delay of two years while they linked the adjuvant to the peptide.. If they did a license deal that would have left that vaccine out of scancell control, But lindy clearly had discovered homocitrulline and she knew that it can be used as a combo to each other. So all of a sudden just like SCIB1 and PD1 .. they become difficult to separate .. because Lindy cannot announce homocitrulline because of the patent ..she would have under valued Modi1 because of the potential to combo .. thus Shareholders would have lost a extremely valuable resource because Lindy could not license Modi1 as a Package ...

which is why i keep saying now the pipeline is cancer ... and deals will be done based on a structure that identifies the compatibility of each license to another and everyone is working to the same goal ... the spin off from that its very very commercial as a project because you are offering a packaged treatment ...

Modi 3

lol .........

Right wing Conservative on a Liberal BOD .... ?

who is JC .........

again if you want tp promote the share why are you taking such short cuts ? any one reading would not have a clue

those in the bubble are talking to themselves

who is CH and LD ?

I keep trying to explain we are NOT privy to the actually situation at any one time because of Patents .... Scancell doing something that we might consider strange like for instance not rushing into a deal with Moditope ... is because we did not know they had applied for the CRUK Grant and the pending patent application for Homocitrulline, so the market has taken the share down because it considers it a delay .. but it never actually has the full facts .. now we are seeing it as a project involving many facets all coming together ... Lindy is NOT cutting corners indeed because the Hydrophobic epitopes are the best ones to use, they challenged themselves to achieve manufacture.

You only get one shot on trial ... and the cost of getting that trial wrong is Millions ... I trust Lindy because she will not accept second best ..

I am just pointing out that its more to do with Shareholders not understanding Scancell rather than the BOD not understanding what they are doing

C7 ,,,,,,,,,, 2015 AGM SP """after"""" was 25p .. so it's not relevant ...

what i have been posting about ref Moditope and the way this all can slot in as a program .... is relative to the US

Assistant Professor of Surgery

Professor Vinod Balachandran

Country: USA
Organisation: Memorial Sloan Kettering Cancer Center
Discipline: Surgical oncology

Vice President of Genentech

Professor Ira Mellman

Country: USA
Organisation: Genentech
Discipline: Cancer immunology



Professor Pandurangan Vijayanand
Associate Professor of Vaccine Discovery

Country: USA
Organisation: La Jolla Institute for Allergy & Immunology
Discipline: Immunology

Professor Jedd Wolchok
Professor of Clinical Investigation

Country: USA
Organisation: Memorial Sloan Kettering Cancer Center
Discipline: Medical oncology, immunotherapy

so it would appear a US office for Moditope is best left open ....

and we are running a US trial ...

2015 was a long time ago in business terms, management has now changed, so not sure why it keeps been discussed ?

Its not me trying to close the discussion, its just that its not representative of the current management

with the latest talk they may buy back all the council houses sold ... LOL we are entering the era of "Stingray"

"anything can happen in the next 5 mins"

maybe best to, before jezza nationalise's the economy ... and declares Communism has cured cancer